‘Eye-Popping Cost Of Redundancy:’ Will US Market Find Place For RSV Prevention Meds And Vaccines?

 
• By Sarah Karlin-Smith and Derrick Gingery

A CDC work group seems to be leaning towards recommending choosing either Pfizer’s maternal vaccination for infant RSV or AstraZeneca/Sanofi’s preventative antibody treatment in babies but not both, in part due to the high costs. What happens to the already available Synagis antibody is another wildcard. 

Child on respirator
RSV prevention medications and vaccines may fill specific niches when on the market together. • Source: Shutterstock

More from Vaccines

More from Pink Sheet